Free Access
Med Sci (Paris)
Volume 19, Number 1, Janvier 2003
Page(s) 43 - 53
Section M/S Revues
Published online 15 January 2003
  1. Boon T, Brichard VG, Eynde BVD. Antigènes de rejet des tumeurs et immunothérapie spécifique du cancer. Med Sci 1995; 11: 1279–87. [Google Scholar]
  2. Eynde BJVD, Gaugler B, Probst-Kepper M, et al. A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription. J Exp Med 1999; 190: 1793–800. [Google Scholar]
  3. Rodriguez A, Regnault A, Kleijmeer M, Ricciardi- Castagnoli P, Amigorena S. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1999; 1: 362–8. [Google Scholar]
  4. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301–5. [Google Scholar]
  5. Imler J, Hoffman J. Toll receptors in innate immunity. Trends Cell Biol 2001; 11: 304–11. [Google Scholar]
  6. Delneste Y, Magistrelli G, Gauchat J, et al. Involvement of Lox-1 in dendritic cell mediated antigen cross-presentation. Immunity 2002; 17: 353–62. [Google Scholar]
  7. Banchereau J, Schuler- Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell 2001; 106: 271–4. [Google Scholar]
  8. Barry M, Bleackley RC. Cytotoxic lymphocytes: all roads lead to death. Nat Immunol 2002; 2: 401–9. [Google Scholar]
  9. Tjelle TE, Lovdal T, Berg T. Phagosome dybnamics and function. Bioessays 2000; 22: 255–63. [Google Scholar]
  10. Grommé M, Uytdehaag FG, Janssen H, et al. Recycling MHC class I molecules and endosomal peptide loading. Proc Natl Acad Sci USA 1999; 96: 10326–31. [Google Scholar]
  11. Pittet MJ, Speiser DE, Valmori D, et al. Ex vivo analysis of tumor antigen specific CD8+ T cell responses using MHC/peptide tetramers in cancer patients. Int Immunolpharmacol 2001; 1: 1235–47. [Google Scholar]
  12. Bonotte B, Favre N, Moutet M, et al. Bcl2-mediated inhibition of apoptosis prevents immunogenicity and restores tumorigenicity of spontaneously regressive tumors. J Immunol 1998; 161: 1433–8. [Google Scholar]
  13. Almand B, Clark JI, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001; 166: 678–89. [Google Scholar]
  14. Pardoll DM. Cancer vaccines. Nat Med 1998; 4 (suppl): 525–31. [Google Scholar]
  15. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000; 101: 455–8. [Google Scholar]
  16. Chouaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A, Blay JY. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today 1997; 18: 493–7. [Google Scholar]
  17. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res 2000; 20: 2665–76. [Google Scholar]
  18. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin- 2, recombinant human interferon alpha- 2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998; 338: 1272–8. [Google Scholar]
  19. Mulé JJ, Shu S, Schwarz SL, Rosenberg SA. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 1984; 225: 1487–9. [Google Scholar]
  20. Rosenberg S, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233: 1318–21. [Google Scholar]
  21. Bouet-Toussaint F, Genetet N, Rioux-Leclercq N, et al. Interleukin 2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer. Eur Cytokine Netw 2000; 11: 217–24. [Google Scholar]
  22. Figlin R, Pierce W, Kaboo R, et al. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8+ selected tumor infiltrating lymphocytes from primary tumor. J Urol 1997; 158: 740–5. [Google Scholar]
  23. Dreno B, Nguyen JM, Khammari A, et al. Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 2002; 51: 539–46. [Google Scholar]
  24. Biragyn A, Kwak LW. Designer cancer vaccines are still in fashion. Nat Med 2000; 6: 966–8. [Google Scholar]
  25. Liau LM, Black KL, Prins RM, et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 1999; 90: 1115–24. [Google Scholar]
  26. Zitvogel L, Mayodormo J, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic celles: dependence on T cells, B7 costimulation, and T helper cell-1 associated cytokines. J Exp Med 1996; 183: 87–97. [Google Scholar]
  27. Lespagnard L, Mettens P, Verheyden AM, et al. Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity. Int J Cancer 1998; 13: 250–8. [Google Scholar]
  28. Wang J, Saffold S, Cao X, Krauss J, Chen W. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 1998; 161: 5516–24. [Google Scholar]
  29. Murphy G, Tjoa B, Ragde H, et al. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996; 29: 371–80. [Google Scholar]
  30. Nestlé FO, Alijagic S, Gilliet M, et al. 1998. Vaccination of melanoma patients with peptide or tumor lysatepulsed dendritic cells. Nat Med 1998; 4: 328–32. [Google Scholar]
  31. Kugler A, Stuhler G, Walden P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000; 6: 332–6. [Google Scholar]
  32. Dudley ME, Wunderlich JR, Yang JC, et al. A phase I study of non myeloablative chemotherapy and adoptive transfer of autologous tumor-antigen specific T lymphocytes in patients with metastatic melanoma. J Immunother 2002; 25: 243–51. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.